Platinum resistance: the role of DNA repair pathways
- PMID: 18316546
- DOI: 10.1158/1078-0432.CCR-07-2238
Platinum resistance: the role of DNA repair pathways
Abstract
Although platinum chemotherapeutic agents such as carboplatin, cisplatin, and oxaliplatin are used to treat a broad range of malignant diseases, their efficacy in most cancers is limited by the development of resistance. There are multiple factors that contribute to platinum resistance but alterations of DNA repair processes have been known for some time to be important in mediating resistance. Recently acquired knowledge has provided insight into the molecular mechanisms of DNA repair pathways and their effect on response to chemotherapy. This review will discuss the most important DNA repair pathways known to be involved in the platinum response, i.e., nucleotide excision repair (NER) and mismatch repair (MMR), and will briefly touch on the role of BRCA in DNA repair. The therapeutic implications of alterations in DNA repair which affect response to platinum in the treatment of patients with malignant disease, such as excision repair cross-complementation group 1 (ERCC1) deficiency and mismatch repair deficiency, will be reviewed.
Similar articles
-
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.Cancer Treat Rev. 1998 Oct;24(5):331-44. doi: 10.1016/s0305-7372(98)90056-1. Cancer Treat Rev. 1998. PMID: 9861196 Review.
-
Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?Cancer Lett. 2014 May 1;346(2):163-71. doi: 10.1016/j.canlet.2014.01.005. Epub 2014 Jan 21. Cancer Lett. 2014. PMID: 24462818 Review.
-
Platinum drugs and DNA repair mechanisms in lung cancer.Anticancer Res. 2014 Jan;34(1):493-501. Anticancer Res. 2014. PMID: 24403507 Review.
-
Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.Clin Exp Pharmacol Physiol. 2014 Oct;41(10):817-24. doi: 10.1111/1440-1681.12282. Clin Exp Pharmacol Physiol. 2014. PMID: 25115435
-
Ongoing and unsaid on oxaliplatin: the hope.Br J Cancer. 1998 Jun;77 Suppl 4(Suppl 4):8-11. doi: 10.1038/bjc.1998.429. Br J Cancer. 1998. PMID: 9647613 Free PMC article. Review.
Cited by
-
What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review.Int J Nanomedicine. 2024 Sep 14;19:9503-9547. doi: 10.2147/IJN.S469217. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39296940 Free PMC article. Review.
-
The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.Cells. 2023 Dec 26;13(1):49. doi: 10.3390/cells13010049. Cells. 2023. PMID: 38201253 Free PMC article.
-
ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.Pharmgenomics Pers Med. 2011;4:47-63. doi: 10.2147/PGPM.S20317. Epub 2011 Jul 20. Pharmgenomics Pers Med. 2011. PMID: 23226053 Free PMC article.
-
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.Gynecol Oncol. 2012 May;125(2):421-6. doi: 10.1016/j.ygyno.2012.01.008. Epub 2012 Jan 16. Gynecol Oncol. 2012. PMID: 22261301 Free PMC article.
-
Platinum Complexes in Colorectal Cancer and Other Solid Tumors.Cancers (Basel). 2021 Apr 25;13(9):2073. doi: 10.3390/cancers13092073. Cancers (Basel). 2021. PMID: 33922989 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
